VCRE (Vicore Pharma Holding AB) Debt-to-Equity: 0.00 (As of Mar. 2026)

What is Vicore Pharma Holding AB Debt-to-Equity?

Vicore Pharma Holding AB VCRE -4.00% 13 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates VCRE with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 964 Biotechnology companies, Vicore Pharma Holding AB ranks worse than 103734.34% on this metric.

Vicore Pharma Holding AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Vicore Pharma Holding AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Vicore Pharma Holding AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $106.35 Mil. Vicore Pharma Holding AB's debt to equity for the quarter that ended in Mar. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vicore Pharma Holding AB's Debt-to-Equity or its related term are showing as below:

VCRE's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Vicore Pharma Holding AB (NAS:VCRE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vicore Pharma Holding AB Debt-to-Equity Related Terms

Vicore Pharma Holding AB Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Debt-to-Equity Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Debt-to-Equity

Get a 7-Day Free Trial

0.00

Vicore Pharma Holding AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Debt-to-Equity	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

VCRE vs : Debt-to-Equity Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Debt-to-Equity falls into.

Save Embed

13GF Score

Vicore Pharma Holding AB VCRE

Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vicore Pharma Holding AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vicore Pharma Holding AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	117.874
	=	0.00

Vicore Pharma Holding AB's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	106.353
	=	0.00

Frequently Asked Questions Learn more about Debt-to-Equity →

What does a Debt-to-Equity of 0.00 mean?

Vicore Pharma Holding AB (VCRE) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vicore Pharma Holding AB and its competitors. According to the industry distribution chart, Vicore Pharma Holding AB ranks #999999 out of 964 companies in the Biotechnology industry.

Is Vicore Pharma Holding AB's Debt-to-Equity too high?

Vicore Pharma Holding AB's current Debt-to-Equity is 0.00. Based on the distribution chart, Vicore Pharma Holding AB ranks #999999 out of 964 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.

How does Vicore Pharma Holding AB's Debt-to-Equity compare to ?

According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #999999 out of 964 companies for Debt-to-Equity. This places Vicore Pharma Holding AB in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-Equity for a Biotechnology company?

The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-Equity mean?

A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vicore Pharma Holding AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vicore Pharma Holding AB's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vicore Pharma Holding AB stock overvalued right now?

Vicore Pharma Holding AB (VCRE) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-Equity calculated?

Debt-to-Equity is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Industry Healthcare Biotechnology

Comparable Companies

Other Exchanges VICO:Sweden 6Y4:Germany

Address Kornhamnstorg 53, Stockholm, SWE, 111 27

Website https://www.vicorepharma.com

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

13GF Score

Get the complete analysis for VCRE

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.60

Price

View VCRE Analysis

See Debt-to-Equity data for all stocks →